Class / Patent application number | Description | Number of patent applications / Date published |
514016000 | 7 or 8 peptide repeating units in known peptide chain | 76 |
20080200396 | Peptides or Peptidic Conjugate Derivatives of Msh and the Use Thereof for Cosmetically Fighting Against Canities - The invention relates to a peptide of formula W-DPhe-Arg-Z (I) and to a conjugate thereof of a formula A-W-DPhe-Arg-Z (II), wherein A is a radical corresponding to a nionocarboxylic acid of general formula HOOC—R (III), wherein R is an linear or branched possibly substituted by a hydroxy group aliphatic C | 08-21-2008 |
20080200397 | PEPTIDOMIMETIC AGENTS FROM DEXTROROTATORY AMINO ACIDS AS WELL AS PHARMACEUTICAL AGENTS THAT CONTAIN THE LATTER FOR TREATMENT OF NEURODEGENERATIVE DISEASES - A peptidomimetic agent from dextrorotatory amino acids includes vGek with Dval-gly-Dglu-Dlys as a central D-amino acid sequence, whereby gly is equal to D-glycine, which is equal to L-glycine. Pharmaceutical agents for use in the treatment of neurodegenerative diseases, in particular Alzheimer's disease, Parkinson's disease, Lewy Body dementia, Creutzfeldt-Jakob disease, as well as Huntington's Chorea disease, multi-system atrophy as well as disorders similar to these neurodegenerative diseases that contain at least one peptidomimetic agent from dextrorotatory amino acids are also included. | 08-21-2008 |
20080207525 | IAP BIR domain binding compounds - Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I or II | 08-28-2008 |
20080207526 | Synthetic peptides and methods of use for autoimmune disease therapies - The invention provides heteropolymer compositions and peptide compositions, and methods of making and using therapeutic compositions comprising amino acid heteropolymers for treatment of a subject for an autoimmune or an inflammatory disease, the heteropolymer compositions made by solid state synthesis. The invention also provides kits for assaying binding of a composition to a water-soluble MHC protein. | 08-28-2008 |
20080227721 | Small peptides for the treatment of alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders - A pharmaceutical composition comprising a peptide consisting of Arg-Val-Ala-Val-Ile-Met-Gly-amide-having at least one D-amino acid. | 09-18-2008 |
20080227723 | Peptides for Preventing or Treating Liver Damage - The application of a peptide having sequence of formula I or its derivant in preparing the medicine for preventing or treating liver damage, especially liver damage and hepatitis C is disclosed, Xaa1-Gln-Xaa2-Xaa3-Thr-Ser-Gly-Xaa4 (formula I) wherein, Xaa1 is deletion, Ala,Gly,Val,Leu or Ile, Xaa2 is Thr or Ser, Xaa3 is Tyr, Phe or Trp, and Xaa4 is deletion, Ala, Gly, Val, Leu,Ile or Pro. The composite medicine containing the said peptide, its preparation method, and the polynucleotide for coding the said peptide are also disclosed. | 09-18-2008 |
20080234205 | Antineoplastic peptides - The present invention provides antineoplastic peptides of formula I, | 09-25-2008 |
20080242618 | Stratification - Provided is the use of a gene-regulatory peptide or functional analogue thereof for the treatment of a disease comprising an inflammatory condition and/or a counter-inflammatory condition wherein a subject suffering from the disease is subjected to a diagnostic process aimed at determining inflammatory disease stage of the subject and where treatment is selected depending on the outcome of the determination of disease stage. | 10-02-2008 |
20080249027 | CHEC-7 a novel sPLA2 inhibitor and methods of use for treating neurological and inflammatory disorders - The present invention relates to the discovery of a composition including a seven-amino acid peptide that promotes neuronal survival, inhibits inflammation, and is a potent inhibitor of sPL2A, and uses thereof. | 10-09-2008 |
20080280834 | Compounds and methods for inhibiting apoptosis - The invention provides compounds, compositions, and methods for inhibiting apoptosis and for the treatment of conditions related thereto. | 11-13-2008 |
20080287369 | Compositions and Methods for Viscosupplementation - The invention provides viscosupplementation compositions that include hyaluronic acid, or a polymer thereof and tribonectin. Such compositions are useful for the lubrication and chondroprotection of mammalian joints. | 11-20-2008 |
20080312158 | Semaphorin Gene Family - A novel class of proteins, semaphorins, nucleic acids encoding semaphorins, semaphorin peptides, and methods of using semaphorins and semaphorin-encoding nucleic acids are disclosed. Semaphorin peptides and receptor agonists and antagonists provide potent modulators of nerve cell growth and regeneration. The invention provides pharmaceutical compositions, methods for screening chemical libraries for regulators of cell growth/differentiation; semaphorin gene-derived nucleic acids for use in genetic mapping, as probes for related genes, and as diagnostic reagents for genetic neurological disease; specific cellular and animal systems for the development of neurological disease therapy. | 12-18-2008 |
20080318871 | Treatment of neurological disorders - The description relates to the treatment of the inflammatory component of neurological disorders or so called neuroimmune disorders such as schizophrenia, manic depression and other bipolar disorders, multiple sclerosis, post-partum psychosis and autism, herein also called inflammatory neurological disorders. Provided are methods for modulating a neurological disorder in a subject comprising providing the subject with a gene-regulatory peptide or functional analogue thereof. Also provided is use of an NF-kappaB down-regulating peptide or functional analogue thereof for the production of a pharmaceutical composition for the treatment of a neurological disorder. | 12-25-2008 |
20090023662 | Identification of Agonistic Autoantibodies Associated with Humoral Kidney Rejection - The invention relates to a method for detecting autoantibodies associated with humoral kidney rejection, which recognize extracellular structures of G protein-coupled receptors, and to the use of peptides, which comprise these loops or fragments thereof, for treating humoral kidney rejection. | 01-22-2009 |
20090054349 | Peptides for Promoting Hair Growth and Improving Wrinkle and Cosmetic Compositions Comprising the same - The present invention relates to a peptide comprising a specific amino acid sequence possessing human thymosin β-4 (Tβ4) activities and its uses. The peptide of this invention has identical or similar functions or actions to human Tβ4 and its biological activity is almost identical to natural-occurring Tβ4. In addition, the peptide of this invention exhibits much higher stability and skin permeation than natural-occurring Tβ4. In these connections, the composition comprising the peptides of this invention can exhibit excellent efficacies on improvement in thymosin β-4-effective disorders or conditions. In addition, the peptide of this invention can be advantageously applied to drugs, cosmetics, toothpaste and compositions for mouth cleaning and caring, most preferably, cosmetics. Specifically, the peptide of this invention is advantageously applied to cosmetics for promoting hair growth. | 02-26-2009 |
20090062210 | Methods for promoting erythropoiesis - The present invention provides methods, compounds, pharmaceutical compositions, and kits for the augmentation of erythropoiesis by potentiating erythropoietin-induced differentiation with angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II analogues, AII fragments or analogues thereof or AII AT | 03-05-2009 |
20090062211 | CONOPEPTIDES AND METHODS OF USE - Isolation, synthesis and therapeutic use of conotoxin and conophan compounds and related compositions including a new class of conopeptides including the modified amino acid D-γ-hydro-oxyvalinie (D-Hyv=V*) are described herein. These isolated peptides are the first known example of a naturally occurring polypeptide chain containing D-Hyv. The active peptides, termed γ-Hydroxyconophans are heavily hydroxylated small peptides. These peptides contain a definitive structural motif which is a double modification of the polypeptide chain (γ-D-OH-Hyv-Trp). | 03-05-2009 |
20090069246 | Methods for promoting hematopoietic and mesenchymal cell proliferation and differentiation - The present invention provides methods, improved cell culture medium and kits for promoting hematopoietic and mesenchymal stem and lineage-specific cell proliferation and differentiation by growth in the presence of angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II (AII), AII analogues, AII fragments or analogues thereof or AII AT | 03-12-2009 |
20090069247 | USE OF TIGHT JUNCTION ANTAGONISTS TO TREAT INFLAMMATORY BOWEL DISEASE - The present invention provides materials and methods for the treatment of inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis). Materials of the invention may include compositions comprising one or more tight junction antagonists and optionally one or more therapeutic agents. Methods of the invention may comprise treating a subject in need thereof with a composition comprising one or more tight junction antagonists and, optionally one or more therapeutic agents. | 03-12-2009 |
20090075904 | Protein Hydrolysate Enriched In Peptides Inhibiting DPP-IV And Their Use - Disclosed is a protein hydrolysate having DPP-IV inhibiting activity, the hydrolysate being enriched in peptides having a length of 2-8 amino acids comprising at least one proline residue, an isolated peptide derivable from such a protein hydrolysate, or a mixture thereof, and the use of such protein hydrolysate or isolated peptide for the manufacture of a medicament, food supplement, beverage or food product for prophylaxis and/or treatment of a DPP-IV mediated condition, in particular chosen from the group of obesity, type 2 diabetes mellitus and an immunological disorder. | 03-19-2009 |
20090082279 | PEPTIDE ANTAGONISTS OF ZONULIN AND METHODS FOR USE OF THE SAME - Peptide antagonists of zonulin are disclosed, as well as methods for the use of the same. The peptide antagonists bind to the zonula occludens receptor, yet do not physiologically modulate the opening of mammalian tight junctions. | 03-26-2009 |
20090093414 | Hyaluronic Acid-Methotrexate Conjugate - An object of the present invention is to provide a hyaluronic acid-methotrexate conjugate useful as a therapeutic drug for joint disorders. There is provided a hyaluronic acid-methotrexate conjugate useful for the treatment of joint disorders, wherein methotrexate is conjugated with a hydroxy group of hyaluronic acid through a linker containing a peptide chain consisting of 1 to 8 amino acids, and the linker is conjugated with the hyaluronic acid through a carbamate group. | 04-09-2009 |
20090093415 | THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME - [Problem]To provide a therapeutic agent for irritable bowel syndrome (IBS), which is excellent in efficacy and safety. | 04-09-2009 |
20090099093 | Peptide Tyrosinase Inhibitors and Uses Thereof - Disclosed are peptides, which inhibit the enzymatic activity of tyrosinase, as well as formulations and methods for their use in the reduction of skin pigmentation, and methods of administering the inhibitory peptides in a topical formulation. The peptides are characterized by sequences RADRADC and PLG-OH. Methods of skin treatment are also provided, the methods further including use of a peptide characterized by the amino acid sequence SFLLRN. | 04-16-2009 |
20090099094 | Use of Somatostatin Agonists to Treat Medullary Thyroid Carcinoma - The present invention is directed to a method of determining a treatment to effectively combat medullary thyroid carcinoma and to suppress the secretion of calcitonin from medullary thyroid carcinoma cells. The present invention also provides a method of suppressing the secretion of calcitonin from medullary thyroid carcinoma cells and decreasing the rate of proliferation of medullary thyroid carcinoma cells which comprises contacting medullary thyroid carcinoma cells with one or more somatostatin agonists. | 04-16-2009 |
20090105155 | TRUNCATED LHRH FORMULATIONS - The present invention provides a peptide useful for raising an antiLHRH response in an animal. The peptide comprises a first and second region, the first region consisting of a sequence of less than 60 amino acids which comprises at least one T helper cell epitope and the second region consisting of the sequence SYGLRPG. | 04-23-2009 |
20090111755 | METHODS FOR THE USE OF INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II MOLECULES - The present invention relates to compounds, pharmaceutical compositions containing such compounds and methods for their use. In particular, the compounds of the invention are useful for the treatment or prevention of diseases associated with T cell proliferation such as autoimmune diseases and disorders. | 04-30-2009 |
20090118196 | LKKTET And/Or LKKTNT Peptide Compositions Which Are Lyophilized Or In A Form Capable of Being Lyophilized - A composition including a peptide agent including amino acid sequence LKKTET or LKKTNT, a conservative variant thereof, or a stimulating agent that stimulates production of an LKKTET or LKKTNT peptide, or a conservative variant thereof, the composition including at least one amino acid stabilizing agent or lyophilization bulking agent, the composition being in lyophilized form, or in a form capable of being lyophilized. | 05-07-2009 |
20090124557 | Compositions and methods for treating cancer - A composition which comprises a chimeric polypeptide is provided. The chimeric polypeptide having a flagellin amino acid sequence and a mucin 1 amino acid sequence which includes at least a 7 amino acid sequence of the mucin 1 tandem repeat which can be used to elicit an immune response against MUC1—expressing cancerous cells. Also provided is a method of treating cancer such as a cancer of a glandular epithelium in which MUC1 is overexpressed using the composition of the present invention. | 05-14-2009 |
20090124558 | COMPOSITIONS AND METHODS FOR TREATING NEURAL ANOXIA AND SPREADING DEPRESSION - Compositions and methods for protecting neural tissue (e.g., neurons) from anoxia and spreading depression (SD) involve inhibiting the cGMP-dependent protein kinase (PKG) pathway. It was discovered that the PKG pathway plays a crucial role in regulating SD and tolerance to anoxia in the central nervous system (CNS). Inhibition of the PKG pathway greatly reduces SD and increases tolerance to anoxia (i.e., hypoxia), while activation of the pathway exacerbates SD pathology. The compositions and methods can be used to treat any condition associated with SD or anoxia, including stroke, spinal cord injury, neurogenerative disease, dizziness, headaches, and migraines. | 05-14-2009 |
20090131327 | NOGO RECEPTOR FUNCTIONAL MOTIFS AND PEPTIDE MIMETICS RELATED THERETO AND METHODS OF USING THE SAME - The present invention provides novel isolated and purified polynucleotides and polypeptides related to functional motifs of the Nogo receptor 1 (NgR1) and use of peptides mimicking these functional motifs as antagonists to NgR1 ligands, e.g., myelin-associated glycoprotein, oligodendrocyte myelin glycoprotein, Nogo-A, Nogo-66, an antibody to Nogo receptor, an antibody to GT1b, an antibody to p75 neurotrophin receptor, and an antibody to Lingo-1, etc. The invention also provides antibodies to the mimetic peptide antagonists. The present invention is further directed to novel therapeutics and therapeutic targets and to methods of screening and assessing test compounds for treatments requiring axonal regeneration, i.e., reversal of the effects of NgR1 ligand binding to the NgR1 (i.e., producing inhibition of axonal growth). The present invention also is directed to novel methods for treating disorders arising from inhibition of axonal growth mediated by the binding of NgR1 ligands to the NgR1. | 05-21-2009 |
20090137493 | Inhibition of tumor metastases using protein kinase C (PKC) inhibitors - Described are methods for reducing tumor metastasis in an animal by administering an inhibitor of a protein kinase C (PKC) isozyme. | 05-28-2009 |
20090143308 | Yeast membrane protein expression system and its application in drug screening - The invention relates to an in vitro cell based expression system for overexpressing heterologous pump proteins associated with drug resistance into the membrane of the host cell for drug screening applications. | 06-04-2009 |
20090143309 | Isozyme-specific antagonists of protein kinase C - A method of changing or otherwise converting the biological activity of a PKC peptide agonist to a peptide antagonist is described. The method involves substituting one or more amino acid residues so as to effect a change in charge in the peptide and/or to otherwise make the sequence similar to a sequence derived from the PKC binding site on the RACK protein for the respective PKC enzyme. Methods of inhibiting the activity of a PKC enzyme, and various peptide antagonists of εPKC are also disclosed. | 06-04-2009 |
20090156507 | Cell permeable conjugates of peptides for inhibition of protein kinases - The present invention provides inhibitors of protein kinases comprising a molecule having at least a first moiety competent for penetration of the molecule into cells, and a second moiety for having a protein kinase inhibiting effect within the cells. The first moiety is joined to the second moiety through a linker or a spacer. The complex molecules are preferably peptide conjugates having improved cell-permeability, serum stability and kinase selectivity compared to known protein kinase inhibitors. Pharmaceutical compositions that include these protein kinase inhibitors, and methods of using such compositions for treatment of cancers and other diseases associated with protein kinase activity are also disclosed. | 06-18-2009 |
20090197814 | Method of inhibiting the emigration of cells from the intravascular compartment into tissues - A method of inhibiting the emigration of cells from the intravascular compartment into tissues (or through any membrane limiting any body compartment from another) by confronting the cells with an agonist specific for receptors involved with migration of said cells via a receptor thereby making the cell unresponsive to further activation. | 08-06-2009 |
20090197815 | COMBINATION OF SOMATOSTATIN-ANALOGS WITH DOPAMINE- OR GROWTH HORMONE RECEPTOR ANTAGONIST - The present invention concerns a product containing Sandostatin® LAR® at 40 mg/28 days or pasireotide and either a dopamine-agonist, preferably cabergoline, or a growth hormone receptor antagonist, preferably pegvisomant, as a combined preparation for simultaneous, separate or sequential use in acromegalic therapy. In particular, this therapy is useful for treating acromegalic patients not achieving biochemical normalization after at least six-month treatment using at least one somatostatin analogue at conventional regimen. | 08-06-2009 |
20090197816 | Stabilizing Alkylglycoside Compositions and Methods Thereof - The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or variant thereof, for example amylin, a monoclonal antibody, insulin, Peptide T or analog thereof, gastrin, gastrir releasing peptides, gastrin releasing peptide-like (GRP) proteins, epidermal growth factor or analog thereof. | 08-06-2009 |
20090215701 | Enhancement of Iron Chelation Therapy - The present invention provides methods of enhancing the rate of iron release from ferritin. By increasing the amount of iron available for chelation, the invention also provides methods of treating conditions associated with iron overload. The invention also provides in one embodiment agents which are useful for treating iron overload. | 08-27-2009 |
20090215702 | Uv-Induced Dermatitis Inhibitor and Atopic Dermatitis Inhibitor - At least one substance selected from the group consisting of a water-soluble peptide comprising at least one unit selected from the group consisting of an isoleucylglycylseryl unit, a prolylisoleucylglycylseryl unit, a glycylprolylisoleucylseryl unit, a glycylprolylisoleucylglycylthreonyl unit, a prolylisoleucylglycyl unit and a glycylprolylisoleucylglycyl unit and a water-soluble salt thereof can be used as an UV-induced dermatitis inhibitor or atopic dermatitis inhibitor. | 08-27-2009 |
20090253637 | SMALL PEPTIDES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER BETA-AMYLOID PROTEIN DISORDERS - Use of a peptide or pharmaceutical composition comprising Leu-Ala-Phe-Val-Leu-Arg-Lys-amide having at least one D amino acid for the reduction of beta-amyloid protein, modulating APP processing, modulating activity of APP secretases, treatment of beta-amyloid protein diseases and the treatment of Alzheimer's disease. | 10-08-2009 |
20090253638 | Somatostatin Antagonists - The invention features somatostatin antagonists having a D-amino acid at the second residue. | 10-08-2009 |
20090264372 | UTILIZATION OF PEPTIDES AS ACTIVE INGREDIENTS FOR SLIMMING - A method of using proteins of the SIRT family or of polypeptide or peptide fragments of SIRT proteins as an active ingredient for slimming, alone or in combination with at least one other active agent, in a cosmetic composition or for the preparation of a pharmaceutical and/or dermatological composition. The invention also includes the use of the peptides for treatment of cellulite and/or used to decrease, eliminate or prevent excess fat beneath the skin. | 10-22-2009 |
20090281044 | ELASTIN DIGEST COMPOSITIONS AND METHODS UTILIZING SAME - The present invention provides compositions for the therapeutic and/or cosmetic treatment of Elastin comprising tissues. Therapeutic and cosmetic compositions comprising an elastin digest stimulate the endogenous production of Elastin and appear to enhance the elasticity of the skin and provide an external supply of peptide precursors of Elastin that penetrate into the tissue to which it is applied. The present invention describes compositions containing an elastin digest derived from proteolytic digestion of insoluble elastin derived from mammalian ligaments with a protein digesting composition, such as proteinase K. The elastin digest is a mixture of elastin peptides wherein the elastin peptide mixture comprises peptides of the sequence GXXPG, wherein X represents one of the natural amino acids. The elastin digest of the present invention may also comprise epitopes of cytokines, growth factors and di-peptides. Methods of using these elastin digest comprising compositions for treating tissues in need of increased elasticity and or Elastin are described. | 11-12-2009 |
20090318366 | CHOLESTEROL LOWERING PROTEIN HYDROLYSATES - The present invention relates to the production of novel peptides which have a length of between 4 and 8 amino acids and comprises the amino acid sequence -Xaa-Xbb-Xcc-Xdd- or -Xbb-Xcc-Xdd-Xaa-, whereby Xaa and Xcc can be His (H), Arg (R) or Lys (K), and Xbb and Xdd can be Pro (P) or Gly (G). | 12-24-2009 |
20090325887 | PEPTIDES AND REGULATION OF CALCIUM CHANNELS - Calcium channels can be regulated by natural gamma proteins. Herein we disclose embodiments of compositions and methods, particularly involving short peptides which are capable of regulating calcium channel function. Certain short peptides which can inhibit calcium current have structural features from the first transmembrane domain of gamma6 such as a GxxxA motif and adjoining aliphatic residues. In embodiments the peptide compositions and methods are capable of selective efficacy for low voltage-activated calcium channels, such as LVA channel Cav3.1, versus high voltage-activated channels. | 12-31-2009 |
20100004182 | COMPOSITION EFFECTIVE TO PREVENT OR TREAT ADULT DISEASE - Disclosed is a composition comprising, as an active ingredient, an enzyme digest that is produced by digesting a basic fraction of an animal-derived cartilage extract with an enzyme. Also disclosed is a polypeptide composition comprising, as an active ingredient, at least one polypeptide selected from specific polypeptides including a polypeptide comprising an amino acid sequence depicted in any one of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10. | 01-07-2010 |
20100016242 | MYOSIN LIGHT CHAIN KINASE INHIBITORS AND METHODS OF USE - Disclosed are inhibitors of myosin light chain kinase, pharmaceutical compositions and kits comprising the inhibitors and methods of use. | 01-21-2010 |
20100035823 | LIGANDS OF SH3 DOMAINS - Provided are compounds that bind to SH3 domains. Also provided are combinatorial libraries for discovering such compounds. Methods of identifying a compound that binds to an SH3 domain are also provided. Methods of inhibiting an activity of a protein comprising an SH3 domain are additionally provided. Additionally provided are methods of inhibiting the activity of a protein comprising an SH3 domain and methods of treating a mammal having a deleterious condition that is mediated by a protein comprising an SH3 domain. The use of a compound that binds to the SH3 domain of a protein kinase in the manufacture of a medicament for the treatment of a deleterious condition in a mammal that is dependent on a protein kinase for induction or severity are also provided. | 02-11-2010 |
20100041614 | METASTASIS-SPECIFIC PEPTIDES AND THEIR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS - The present invention concerns peptide sequences that specifically recognize cells of human hepatic metastases. The invention comprises also the use of nucleic acids coding for such peptides, as well as conjugates and formulations of such peptides for diagnostic and therapeutic purposes. | 02-18-2010 |
20100048490 | BINDING LIGAND LINKED DRUG DELIVERY CONJUGATES OF TUBULYSINS - Described herein are compounds, pharmaceutical compositions and methods for treating pathogenic cell populations. The compounds described herein include conjugates of tubulysins and vitamin receptor binding ligands. The conjugates also include a releasable bivalent linker. | 02-25-2010 |
20100069308 | Surfaces containing antibacterial polymers - This invention provides a surface that has been coated with anti-bacterial polymers. Such surfaces would be suitable for use in, for example, medical devices and public surfaces. Additionally, the invention provides a method for coating surfaces with the anti-bacterial polymer. | 03-18-2010 |
20100087380 | PHARMACEUTICAL COMPOSITIONS FOR INHIBITING INTESTINAL PERMEABILITY - A method for preventing or delaying the onset of autoimmune diseases is disclosed. | 04-08-2010 |
20100093641 | SILK PROTEIN-MIMICKING PEPTIDES AND COMPOSITIONS FOR PREVENTING OR TREATING CRANIAL NEUROPATHIES COMPRISING THE SAME - The present invention relates to a silk protein-mimicking peptide represented by the following Formula 1, a composition for preventing or treating a brain disease, a composition for improving a brain or cognitive function and a composition for preventing or treating diseases, disorders or conditions associated with oxidative stress comprising the peptide: | 04-15-2010 |
20100099628 | CARBOHYDRATE-BASED PERITONEAL DIALYSIS FLUID COMPRISING GLUTAMINE RESIDUE - The present invention relates to a carbohydrate-based peritoneal dialysis fluid, containing a compound selected from the group consisting of glutamine, preferably L-glutamine, a dipeptide capable of releasing glutamine, L-glutamine in free form, preferably selected from the group consisting of glutaminyl-glycine, glycinyl-glutamine, glutaminyl-alanine, alanyl-glutamine an oligopeptide consisting of two to seven glutamine, preferably L-glutamine residues, and mixtures thereof. The peritoneal dialysis fluids of the present invention are useful for inhibition of technical failure in a person undergoing peritoneal dialysis treatment. | 04-22-2010 |
20100105627 | PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF DELIVERY - The pharmaceutical compositions described herein include a suspension which comprises an admixture in solid form of a therapeutically effective amount of a therapeutic agent and at least one salt of a medium chain fatty acid and a hydrophobic medium, e.g. castor oil or glyceryl tricaprylate or a mixture thereof. The pharmaceutical compositions described herein contain medium chain fatty acid salts and are substantially free of alcohols. The pharmaceutical compositions may be encapsulated in a capsule. Methods of treating or preventing diseases by administering such compositions to affected subjects are also disclosed. | 04-29-2010 |
20100113367 | PEPTIDE-CYTOTOXIC CONJUGATES - The invention features targeted cytotoxic compounds and methods relating to their therapeutic use for the treatment of neoplasia and other conditions. | 05-06-2010 |
20100113368 | CHOLESTEROL LOWERING PROTEIN HYDROLYSATES - The present invention relates to the production of novel peptides which have a length of between 4 and 8 amino acids and comprises the amino acid sequence -Xaa-Xbb-Xcc-Xdd-, whereby Xaa and Xdd can be His (H), Arg (R) or Lys (K), and Xbb and Xcc can be Pro (P) or Gly (G). | 05-06-2010 |
20100137225 | PHAGE DISPLAYED CELL BINDING PEPTIDES - This disclosure provides the construction, expression, and selection of the mutated genes that encode novel Trp cage polypeptides with desirable binding properties, as well as the novel Trp cage polypeptides themselves. The substances or targets bound by these novel Trp cage polypeptides may be but need not be proteins or polypeptides. Targets may include other biological or synthetic macromolecules as well as other organic and inorganic substances. Further, targets may also include a single or multiple cell or tissue types. The present invention achieves genetic variants of Trp cage-encoding nucleic acids through controlled random mutagenesis of the nucleic acids yielding a mixture of Trp cage polypeptides that are capable of binding targets. | 06-03-2010 |
20100144645 | COMPOSITIONS AND METHODS FOR ENHANCING ANALGESIC POTENCY OF COVALENTLY BOUND-COMPOUNDS, ATTENUATING ITS ADVERSE SIDE EFFECTS, AND PREVENTING THEIR ABUSE - The invention generally relates to compositions and methods with covalently bound compounds, such as controlled substances covalently attached to a chemical moiety, and opioid antagonists or covalently bound opioid antagonists to enhance analgesic potency and/or attenuate one or more adverse effects of covalently bound compounds, including adverse side effect(s) in humans such as nausea, vomiting, dizziness, headache, sedation (somnolence), physical dependence or pruritis. This invention relates to compositions and methods for selectively enhancing the analgesic potency of a covalently bound compound and simultaneously attenuating anti-analgesia, hyperalgesia, hyperexcitability, physical dependence and/or tolerance effects associated with the administration of a covalently bound compound. The methods of the invention comprise administering to a subject an analgesic or sub-analgesic amount of a covalently bound compound and an amount of excitatory opioid receptor antagonist such as naltrexone or nalmefene effective to enhance the analgesic potency of a covalently bound compound and attenuate the anti-analgesia, hyperalgesia, hyperexcitability, physical dependence and/or tolerance effects of covalently bound compound. The invention also relates to the addition of covalently-bound opioid antagonists to the compositions containing covalently bound compounds such that if the compositions are subjected to manipulation by illicit chemists, the opioid antagonist is released effectively reducing or eliminating the euphoric effect of the covalently bound compounds. | 06-10-2010 |
20100144646 | METHOD OF DIAGNOSING AND TREATING ASTHMA - The present invention provides materials and methods to diagnose asthma. In some embodiments, the present invention provides a method of diagnosing asthma by measuring the zonulin level of a subject. The present invention also provides methods and compositions for treating asthma that comprise one or more zonulin antagonist. | 06-10-2010 |
20100152119 | PHARMACEUTICAL AND/OR COSMETIC COMPOSITION CONTAINING PEPTIDES - The present invention concerns the use of peptide fragments of the protein SLC24A5 as active agents designed to induce, increase, or restore the synthesis of melanin in the melanocytes of the epidermis or of the pilar bulb, alone or in association with at least one other active agent, in a cosmetic composition or for the preparation of a pharmaceutical or particularly dermatological composition. The invention is also related to any composition containing the active agents. | 06-17-2010 |
20100152120 | METHODS AND APPARATUS FOR THE ENHANCED DELIVERY OF PHYSIOLOGIC AGENTS TO TISSUE SURFACES - Apparatus and methods deliver physiologically active agents in the presence of adjuvant gases. The adjuvant gases can enhance the effectiveness of the drug, lower the dosage of drug or concentration of drug necessary to achieve a therapeutic result, or both. Exemplary adjuvant gases include carbon dioxide, nitric oxide, nitrous oxide, and dilute acid gases. | 06-17-2010 |
20100168037 | PEPTIDES COMPRISING AROMATIC D-AMINO ACIDS AND METHODS OF USE - Disclosed are D-peptides and libraries of D-peptides comprising aromatic D-amino acids. Also disclosed are methods for identifying small D-peptides comprising aromatic D-amino acids that bind to proteins of interest | 07-01-2010 |
20100184701 | Beta-Arrestin Effectors And Compositions And Methods Of Use Thereof - This application describes a family of compounds acting as β-arrestin effectors. Such compounds may provide significant therapeutic benefit in the treatment of chronic and acute cardiovascular diseases. | 07-22-2010 |
20100197604 | USE OF PEPTIDE AS A THERAPEUTIC AGENT - The present invention is directed to the use of the peptide compound Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent. | 08-05-2010 |
20100197605 | THERAPEUTIC USE OF PEPTIDE YGLF AND COMBINATION WITH KVLPVPQ - The present invention is directed to the use of the peptide compound Tyr-Gly-Leu-Phe-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Tyr-Gly-Leu-Phe-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent. | 08-05-2010 |
20100204147 | Methods For Delivering Thymosin Beta 4, Analogues, Isoforms and Other Derivatives - A composition and method utilizes a substantially purified composition including an adhesive and a polypeptide containing amino acid sequence LKKTET or a conservative variant thereof. | 08-12-2010 |
20100204148 | (D-LEU7 ) -HISTRELIN AS A THERAPEUTIC AGENT - The present invention is directed to the use of the peptide compound Pyr-His-Trp-Ser-Tyr-D-His(Bzl)-D-Leu-Arg-Pro-NHEt as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Pyr-His-Trp-Ser-Tyr-D-His(Bzl)-D-Leu-Arg-Pro-NHEt optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent. | 08-12-2010 |
20100204149 | USE OF OCTREOTIDE AS A THERAPEUTIC AGENT - The present invention is directed to the use of the peptide compound H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-L-threoninol as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-L-threoninol optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent. | 08-12-2010 |
20100204150 | USE OF A PEPTIDE AS A THERAPEUTIC AGENT - The present invention is directed to the use of the peptide compound His-Pro-Phe-His-Leu-D-Leu-Val-Tyr-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide His-Pro-Phe-His-Leu-D-Leu-Val-Tyr-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent. | 08-12-2010 |
20100204151 | USE OF A PEPTIDE AS A THERAPEUTIC AGENT - The present invention is directed to the use of the peptide compound Ac-His-Trp-Ala-VaI-GIy-HiS-LeU-NH | 08-12-2010 |
20100204152 | USE OF GLUTEN EXORPHIN C : AS A THERAPEUTIC AGENT - The present invention is directed to the use of the peptide compound Ala-Val-Pro-Tyr-Pro-Gln-Arg-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquide buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Ala-Val-Pro-Tyr-Pro-Gln-Arg-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent. | 08-12-2010 |
20100210565 | METHODS AND APPARATUS FOR THE ENHANCED DELIVERY OF PHYSIOLOGIC AGENTS TO TISSUE SURFACES - Apparatus and methods deliver physiologically active agents in the presence of adjuvant gases. The adjuvant gases can enhance the effectiveness of the drug, lower the dosage of drug or concentration of drug necessary to achieve a therapeutic result, or both. Exemplary adjuvant gases include carbon dioxide, nitric oxide, nitrous oxide, and dilute acid gases. | 08-19-2010 |
20100216724 | USE OF FIBRONECTIN FRAGMENT (196-203 ) AS A THERAPEUTIC AGENT - The present invention is directed to the use of the peptide compound Ser-Arg-Asn-Arg-Cys-Asn-Asp-Gln-NH | 08-26-2010 |
20100234306 | USE OF A PEPTIDE AS A THERAPEUTIC AGENT - The present invention is directed to the use of the peptide compound Met-Gln-Met-Lys-Lys-Val-Leu-Asp-Ser-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Met-Gln-Met-Lys-Lys-Val-Leu-Asp-Ser-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent. | 09-16-2010 |